Trial 0C-17-2

A Phase 1 Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects with Advanced Cancers

Type: Treatment
Phase: Phase I
Status: Open to Accrual
Treatments: Biological Response Modifier, Chemotherapy: Systemic
Randomized: No
Defintions of terms and FAQ about clinical trials.

Trial Leaders/Researchers: David Quinn, M.D.
Other Trial Staff: Cheryl Kefauver, Coordinator, Yan Ning, D.M., Lorraine Martinez, Coordinator, Nicole Jensen, Coordinator, Rishi Bhavsar, Coordinator, Anayansi Miloud, D.M., Anayansi Miloud, D.M., Xiomara Menendez, Coordinator, Jessica Levano, Coordinator, Arthur Alvarez, D.M., Khatchik Karakozian, D.M., Khatchik Karakozian, D.M., Kseniia Kulakova, D.M., Cristina Lee, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov

For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.